SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
MaxLinear held its Annual Meeting of Stockholders on May 20, 2026, with shareholders voting on five matters: election of two Class II directors, advisory vote on named executive officer compensation, ratification of Grant Thornton LLP as independent auditor, and approval of amendments to the 2010 Equity Incentive Plan and 2010 Employee Stock Purchase Plan (including a new ten-year term and increase of 3,204,107 shares reserved).
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of $15 million in consolidated obligation bonds (CUSIP 3130BAU47, maturing 5/27/2031, 4.875% coupon) by the Federal Home Loan Bank of San Francisco on trade date 5/19/2026. While Item 2.03 is nominally about "creation of a direct financial obligation," the filing itself states that "consolidated obligations issuance is material to the Bank" and the Bank has not made materiality judgments on particular obligations. This is a routine debt issuance disclosure for a government-sponsored enterprise (FHLB), not a covenant breach, going-concern issue, or other acute financial stress signal. The event is material to investors as it affects the Bank's capital structure and leverage, but does not fit neatly into more specific event categories (e.g., it is not a breach, impairment, or M&A activity), warranting classification as other_material.
View raw filing on EDGAR →This Item 2.03 disclosure describes the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Des Moines. While the filing creates direct financial obligations through debt issuance, the prose is primarily explanatory and regulatory in nature, describing the general framework and mechanics of consolidated obligations rather than disclosing a specific new obligation event. The filing explicitly states "we have not made a judgment as to the materiality of any particular consolidated obligation or obligations," suggesting this is a routine periodic disclosure of debt issuance activity rather than a discrete material event. This does not fit cleanly into the more specific event types (covenant_breach, going_concern, etc.) and is best classified as other_material given the inherent materiality of debt issuance to a financial institution.
View raw filing on EDGAR →This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) totaling approximately $890 million across eight separate securities issued on trade dates 05/18/2026 and 05/19/2026. While Item 2.03 is the designated item for direct financial obligations, the taxonomy lacks a specific "debt_issuance" category. The disclosure is material to investors as it represents significant new debt obligations for the FHLBank, though the filing itself notes the FHLBank has not made a materiality judgment on individual obligations. This is classified as "other_material" rather than a more specific event type because debt issuance activity, while routine for a Federal Home Loan Bank, does not fit cleanly into the provided taxonomy categories.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of Consolidated Bonds ($19.5M and $15.5M par amounts) by the Federal Home Loan Bank of Cincinnati on trade dates 5/19/2026. While Item 2.03 is technically designated for "Creation of a Direct Financial Obligation," the filing itself explicitly states "although Consolidated Obligations issuance is material to the FHLB, we have not made a judgment as to the materiality of any particular Consolidated Obligation or Obligations." The disclosure does not fit cleanly into the covenant_breach taxonomy (no breach alleged) and represents routine debt issuance rather than a discrete material event like M&A, impairment, or executive change. The materiality assertion combined with the routine nature of debt issuance for a Federal Home Loan Bank suggests classification as other_material rather than a more specific event type.
View raw filing on EDGAR →Workday issued a press release on May 21, 2026 announcing results for its fiscal quarter ended April 30, 2026, attached as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02, which is material to investors as it provides financial performance data for the period.
View raw filing on EDGAR →This Item 2.03 disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Pittsburgh. While the filing explicitly states "consolidated obligations issuance is material to the FHLBank," the disclosure is primarily informational and regulatory in nature—describing the mechanics of consolidated obligation issuance, the joint and several liability structure, and referencing Schedule A for specific debt instruments. This does not fit cleanly into covenant_breach (no violation alleged) or the more specific debt-related categories, making other_material the most appropriate classification for this regulatory debt disclosure.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of consolidated obligations (bonds and discount notes) totaling approximately $781 million across multiple tranches with varying maturities and coupon rates. While Item 2.03 is technically designated for "Creation of a Direct Financial Obligation," the filing itself explicitly states "although consolidated obligations issuance is material to the Bank, we have not made a judgment as to the materiality of any particular consolidated obligation or obligations." The disclosure is routine for a Federal Home Loan Bank's ordinary course debt issuance operations, not a discrete material event like a covenant breach or going-concern issue. This is best classified as other_material rather than covenant_breach, as it represents standard debt capital-raising activity rather than a triggering financial stress event.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of consolidated obligations (bonds and discount notes) totaling approximately $293 million across seven separate debt securities issued in May 2026. While Item 2.03 typically signals covenant_breach or direct financial obligations arising from adverse events, this filing discloses routine debt issuances by a Federal Home Loan Bank to fund operations—a standard capital markets activity. The disclosure is material to investors as it reflects the Bank's funding activities and debt structure, but does not fit the specific event types (covenant_breach, ma_activity, or dilutive_issuance) as cleanly as other_material, since these are consolidated obligations jointly backed by all 11 FHLBanks rather than a discrete triggering event or breach.
View raw filing on EDGAR →This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) totaling approximately $505 million across five separate debt securities issued in May 2026. While Item 2.03 is technically designed for covenant_breach events, the filing's explicit focus on debt issuance—a material financing activity for a Federal Home Loan Bank—does not fit cleanly into the covenant_breach category. The disclosure is material to investors assessing the Bank's capital structure and funding activities, but the event itself (routine debt issuance by a government-sponsored enterprise) lacks the distress signal of a covenant violation or the transformative nature of M&A activity.
View raw filing on EDGAR →The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds totaling $260 million with maturities ranging from one to four years. While Item 2.03 typically covers debt covenant breaches or off-balance sheet arrangements, this disclosure is fundamentally about the creation of direct financial obligations through bond issuances. The materiality is clear given the substantial principal amounts and multi-year maturities, but the event does not fit cleanly into the covenant_breach category (no breach is disclosed) and lacks the specific characteristics of other defined event types, warranting classification as other_material.
View raw filing on EDGAR →This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds totaling approximately $2.37 billion across multiple tranches with varying maturities (ranging from 8/20/2026 to 5/26/2056) and rate structures. While Item 2.03 typically signals covenant_breach or material debt obligations, the filing itself explicitly states "the Bank has not made a judgment as to the materiality of these consolidated obligation bonds," and the disclosure is routine debt issuance activity for a Federal Home Loan Bank. The event is material to investors as a significant funding activity, but does not fit cleanly into the more specific event categories (no covenant breach, no going concern, no impairment), making "other_material" the most appropriate classification.
View raw filing on EDGAR →The disclosure announces a quarterly cash dividend declaration of $0.975 per share, which is a material capital allocation decision affecting shareholder returns. While dividend declarations are routine for established dividend-paying companies, this represents a material event to investors assessing the company's financial health and shareholder value distribution. It does not fit the more specific event categories (earnings, M&A, executive changes, etc.) and is best classified as other_material.
View raw filing on EDGAR →Hamilton Lane Incorporated disclosed financial results for the fourth quarter and full fiscal year ended March 31, 2026 via press release and detailed presentation furnished as exhibits to Item 2.02. This is a standard earnings release disclosure that would materially affect a reasonable investor's assessment of the company's financial performance and condition.
View raw filing on EDGAR →Charlie's Holdings entered into subscription agreements for the unregistered private placement sale of 6,350,000 shares of common stock at $0.20 per share under Section 4(a)(2), raising approximately $1.27 million in gross proceeds (including debt forgiveness). The issuance represents significant dilution to existing shareholders.
View raw filing on EDGAR →Skillsoft entered into a Sale and Purchase Agreement on May 20, 2026, to divest its Global Knowledge business for $10 million upfront plus $10 million in deferred consideration over five quarters, as part of a strategic refocus on its core AI-native skills management platform.
View raw filing on EDGAR →Ronald Kisling was appointed as Chief Financial Officer effective May 20, 2026, with compensation terms including a $500,000 base salary, $200,000 signing bonus, 150,000 restricted stock units, and 30,000 performance stock units. John Frederick's retirement as CFO is also disclosed in connection with this transition.
View raw filing on EDGAR →BioCardia disclosed positive preliminary clinical trial results for CardiAMP Cell Therapy presented at a major medical conference (Euro PCR), showing safety (no major adverse cardiac events) and efficacy outcomes (179-second improvement in exercise tolerance, 82% reduction in angina episodes at six months through two-year follow-up). While this is clinical trial data rather than financial results or a traditional earnings release, the positive efficacy and safety findings for a lead therapeutic candidate are material to investors' assessment of the company's pipeline and commercial prospects. This does not fit neatly into the earnings_release category (which typically refers to financial results) but represents a material clinical milestone disclosure.
View raw filing on EDGAR →The filing discloses a special cash distribution of $0.12 per common unit (approximately $4.6 million) approved by the General Partner in addition to scheduled monthly distributions. While routine distributions may not be material, the special distribution—triggered by the Partnership's debt-free status, elevated market prices, and operational cash flow—represents a material capital allocation decision that would affect a reasonable investor's assessment of the Partnership's financial position and distribution policy. This does not fit neatly into the standard taxonomy categories and is best classified as other_material.
View raw filing on EDGAR →This Item 5.07 discloses the results of an Annual Meeting of Shareholders held on May 20, 2026, covering three proposals: election of ten directors, a non-binding advisory vote on executive compensation, and ratification of Elliott Davis, LLC as independent auditors. The filing presents detailed voting tallies for each proposal, which is the core disclosure required under Item 5.07 for shareholder vote results. The material note that Kenneth E. Robison resigned immediately following the meeting adds context but does not change the primary event classification.
View raw filing on EDGAR →This Item 5.07 disclosure presents the final vote results from the May 21, 2026 annual meeting of shareholders on three matters: election of twelve directors, ratification of Plante & Moran as independent auditor, and an advisory vote on named executive officer compensation. The detailed tabulation of votes for each director nominee and each proposal is the core content of a shareholder_vote_results event.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the Company's May 18, 2026 annual meeting of stockholders, with detailed voting tallies for all five proposals presented (director elections, auditor ratification, name change amendment, equity plan amendment, and say-on-pay). The filing directly corresponds to Item 5.07 requirements and would materially inform investors about governance outcomes and shareholder approval of key corporate matters.
View raw filing on EDGAR →The filing discloses both a director departure (Lewis Titterton's retirement on May 15, 2026) and a director appointment (Anthony Bowers appointed on May 19, 2026). While both events are present, the prose centers on the appointment as the principal action—Bowers was "unanimously appointed" to fill the vacancy and assigned to key committees (Audit and Compensation). The appointment of a director to sensitive committees is material to investors assessing board composition and governance, making this an exec_appointment event.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of Avidbank Holdings' 2026 Annual Meeting of Shareholders held on May 19, 2026, including voting outcomes for two proposals: (1) election of ten directors, with detailed vote tallies for each nominee, and (2) ratification of Crowe LLP as the independent registered public accounting firm. The disclosure of shareholder meeting results is the core purpose of Item 5.07 and is material to investors assessing board composition and auditor selection.
View raw filing on EDGAR →This is a clear disclosure of shareholder meeting results under Item 5.07, reporting the voting outcomes for two proposals: (1) election of fifteen directors with detailed vote tallies for each nominee, and (2) ratification of Elliott Davis, PLLC as independent auditor. The filing presents the formal voting results from the May 19, 2026 Annual Meeting of Shareholders.
View raw filing on EDGAR →The filing discloses a delisting risk event: Aterian received a Nasdaq notice on December 9, 2025 that it failed to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2), triggering a 180-day cure period. Although the company subsequently regained compliance by May 19, 2026, the core event disclosed is the delisting notice and the company's status relative to continued listing standards. This is material to investors as it directly affects the registrant's exchange listing status.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from ECB Bancorp's annual meeting held May 20, 2026, reporting the election of directors (Joseph Sachetta and Susan Sgroi) and ratification of Wolf & Company, P.C. as independent auditor. Item 5.07 explicitly requires disclosure of voting results, and director elections and auditor ratification are material governance matters affecting investor assessment of board composition and audit oversight.
View raw filing on EDGAR →Apyx Medical announced publication of clinical data in a peer-reviewed journal (Aesthetic Surgery Journal Open Forum) demonstrating efficacy for cellulite and skin laxity treatment. While this is a positive clinical validation event relevant to the company's product portfolio and market positioning, it does not fit neatly into the more specific event categories (not earnings, M&A, litigation, impairment, etc.). The disclosure is material to investors assessing the company's clinical evidence base and competitive standing in aesthetic medicine, but the ambiguity about whether this constitutes a "material" event versus routine clinical publication reporting warrants moderate confidence.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from DiaMedica's 2026 Annual General Meeting held on May 20, 2026, filed under Item 5.07. The filing presents final voting tallies for four proposals: director elections, auditor ratification, advisory executive compensation approval, and an omnibus incentive plan amendment. All proposals passed, and the detailed vote counts are material to investors assessing board composition, audit oversight, and equity dilution.
View raw filing on EDGAR →National Presto Industries held its Annual Meeting of Stockholders on May 19, 2026, with shareholders voting on and approving three proposals: election of directors (Lieble and Stienessen), ratification of RSM US LLP as independent auditor, and an advisory vote on executive compensation.
View raw filing on EDGAR →Tandem Diabetes Care held its 2026 Annual Meeting of Stockholders on May 20, 2026, with shareholders voting on six proposals: election of nine directors, advisory vote on named executive officer compensation, approval of an amended 2023 Long-Term Incentive Plan increasing authorized shares by 3,260,000, amendments to the Certificate of Incorporation regarding director removal and officer liability limitations, and ratification of Ernst & Young LLP as independent auditor. All proposals passed with substantial majorities.
View raw filing on EDGAR →Travere Therapeutics held its Annual Meeting of Stockholders on May 19, 2026, with shareholders voting on five proposals: election of ten directors, approval of an amendment to the 2018 Equity Incentive Plan increasing authorized shares by 3,000,000, advisory approval of named executive officer compensation, advisory frequency vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor. All five proposals passed with substantial majorities.
View raw filing on EDGAR →Siddharth Thacker, Chief Financial Officer of Rent the Runway, Inc., tendered his resignation effective June 3, 2026. This departure of a named executive officer from a key financial leadership position is material to investor assessment of the company's financial leadership continuity.
View raw filing on EDGAR →The company reaffirmed FY2026 guidance while disclosing an ongoing CEO and CFO search process and highlighting material risks of executive attrition and Board transition. The forward-looking statements emphasize management continuity challenges tied to ongoing executive leadership transitions.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on May 21, 2026. The filing presents voting outcomes for three proposals: election of nine directors, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. Item 5.07 explicitly requires disclosure of shareholder voting results, and the material outcomes (all proposals passed with substantial majorities) are directly relevant to investor assessment of governance and management accountability.
View raw filing on EDGAR →GlobalTech Corporation issued a press release on May 21, 2026 disclosing financial results for the quarter ended March 31, 2026, furnished as Exhibit 99.1 to the Form 8-K under Item 2.02 (Results of Operations and Financial Condition). This is a standard quarterly earnings release disclosure, which is material to investors as it provides key financial performance metrics.
View raw filing on EDGAR →The Company exchanged 1,222 shares of Series B Preferred Stock (stated value $1,222,000) for 3,253,455 shares of common stock in an unregistered transaction under Section 3(a)(9) of the Securities Act. This is a material dilutive issuance of over 3.2 million common shares, which would significantly impact existing shareholders' ownership percentages and is precisely the type of equity capital raise that Item 3.02 is designed to capture.
View raw filing on EDGAR →The filing discloses an amendment to an at-the-market (ATM) offering program increasing capacity to $3,660,000 of Class A Common Stock shares. This is a dilutive equity issuance mechanism that provides the company with ongoing access to capital markets. The company has already sold $4,367,863 of shares under the prior ATM prospectus supplement, demonstrating active use of this dilutive financing vehicle.
View raw filing on EDGAR →The filing discloses announcement of tokenized equity listing on xStocks via press release (Exhibit 99.1), filed under Item 7.01 (Regulation FD Disclosure). This represents a material corporate development—the introduction of a blockchain-based equity instrument—that does not fit cleanly into standard 8-K categories (not M&A, not earnings, not an executive change). The tokenization of equity is a novel capital structure event that would affect investor assessment of the company's business model and equity structure.
View raw filing on EDGAR →The filing discloses interim clinical trial results from the Phase 2 NEXICART-2 trial showing that all four MRD-negative relapsed/refractory AL Amyloidosis patients have converted to complete response (CR), with a 95% CR rate (19/20) across the first 20 patients and no relapses observed. While this is positive clinical progress for a biopharmaceutical company's lead candidate, it does not fit neatly into the standard event taxonomy—it is neither an earnings release (no financial results), nor a material impairment, litigation, M&A activity, or executive change. The disclosure is material to investors assessing the company's pipeline and regulatory prospects, but the event is best classified as other_material given the clinical-trial-update nature of the announcement.
View raw filing on EDGAR →The filing discloses entry into a Fully Binding Letter of Intent (Term Sheet) dated May 20, 2026, involving a material multi-party transaction. The Company would acquire or license intellectual property from EOS and SCLX, expand its Datavault license, and acquire a controlling interest in Health Lives Here from HBA. Upon conversion of Acquisition Preferred, the transaction parties would own approximately 89.6% of the Company's common stock, representing a substantial change of control. The proposed combined entity valuation is stated at $4.0 billion. While subject to definitive agreements and conditions, this constitutes entry into a material definitive agreement for M&A activity under Item 1.01.
View raw filing on EDGAR →Co-Diagnostics entered into a private placement on May 19, 2026, issuing 54,915 shares of common stock, 1,592,532 pre-funded warrants, and 3,294,894 common warrants for aggregate gross proceeds of $3.0 million. The filing explicitly discloses the Securities Purchase Agreement with institutional and accredited investors, detailed warrant terms, and registration rights obligations. This is a classic dilutive equity issuance (PIPE-like structure with warrants) that materially affects shareholder ownership and capital structure.
View raw filing on EDGAR →Jupiter Neurosciences entered into a Securities Purchase Agreement on May 20, 2026, to issue 7,142,858 shares of common stock at $0.28 per share in a registered direct offering, raising approximately $2.0 million in gross proceeds. This is a registered equity issuance that will dilute existing shareholders and is material to investors assessing the company's capital structure and financing activities.
View raw filing on EDGAR →The filing discloses Item 5.07 results from Landmark Bancorp's Annual Meeting of Stockholders held May 20, 2026, including voting outcomes on three proposals: election of three Class I directors (Angela S. Hurt, David H. Snapp, and Angelia K. Stanland), approval of an amendment to increase authorized common shares from 7.5M to 10M, and ratification of Forvis Mazars, LLP as independent auditor. These are standard shareholder vote results that materially affect corporate governance and capital structure.
View raw filing on EDGAR →AIM ImmunoTech completed an unregistered private placement of Common Warrants and Placement Agent Warrants under Section 4(a)(2) and Rule 506, with pricing announced on May 20, 2026. The offering included a Securities Purchase Agreement and underlying shares, representing a dilutive equity issuance to accredited investors that materially affects shareholder ownership and capital structure.
View raw filing on EDGAR →The 8-K discloses Item 2.02 (Results of Operations and Financial Condition), with I-ON Digital Corp. issuing a press release on May 21, 2026 announcing financial results for the first quarter ended March 31, 2026. The press release is attached as Exhibit 99.1. This is a standard earnings release disclosure that would materially affect a reasonable investor's assessment of the registrant's financial performance.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Steven Madden's 2026 Annual Meeting of Stockholders held on May 20, 2026. The filing reports the final voting tallies for three proposals: election of ten directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote counts (For, Against, Withheld, Abstentions, Broker Non-Votes) for each proposal are the hallmark of Item 5.07 disclosures and constitute material information about corporate governance outcomes.
View raw filing on EDGAR →The filing discloses the appointment of Ronen Tanami as Chief Operating Officer on May 13, 2026, which is the principal action reported. While the Item 5.02 disclosure also includes compensatory details (a 40,000-share option grant), the core event is the executive appointment. The appointment of a COO is material to investors as it reflects a significant change in the company's management structure.
View raw filing on EDGAR →The filing discloses under Item 8.01 (Other Events) that Ocean Power Technologies announced an expansion in its global deployment footprint across U.S. government, international, and research customers via press release. While the specific details of the expansion are not provided in the 8-K body itself, the announcement of expanded deployment across government and international customers could be material to investors assessing the company's growth trajectory and market reach. However, without the full press release text, the precise materiality and nature of the event cannot be definitively categorized into a more specific event type, warranting classification as other_material.
View raw filing on EDGAR →The filing discloses the Board's appointment of Taehoon Kim, the current CEO, to the additional roles of Principal Financial Officer and Principal Accounting Officer, effective immediately on May 18, 2026. This is a material executive appointment that consolidates critical financial and accounting oversight functions under the CEO following the previously announced resignation of CFO Juhyon Shin. The appointment of a principal financial officer is a material event affecting investor assessment of the company's financial governance and leadership structure.
View raw filing on EDGAR →